Tandem Diabetes Care has issued a correction covering more than 80,900 Mobi insulin pumps, most of them in the United States. The action began in late September 2026. FDA posted it on October 30 as database entry 222734.

Affected pumps can raise a false occlusion alarm. The alarm suspends insulin delivery until the user acknowledges it and resumes therapy, so repeated alarms raise the risk of high blood glucose. Tandem traced the cause to increased friction in the drive module, which cuts motor power. Under some conditions motor speed falls below the occlusion detection threshold and the pump reports a blockage that is not there.

Tandem reported 230 events requiring medical intervention or hospitalization as of October 29, 2026. No deaths have been reported. FDA listed serial numbers for pumps with frequent false alarms, which Tandem will exchange, while noting that all affected models and serial numbers may be involved. Patients can keep using their pumps but must answer every occlusion alarm and keep a backup delivery method.

This is the second Mobi correction of 2026. The April action involved a separate software fault that could affect insulin delivery. A mechanical wear path that only shows up as a nuisance alarm is easy to miss in design verification and arrives fast in complaint data.